<!doctype html>
<html lang="en">
  <head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1313&amp;path=livereload" data-no-instant defer></script>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <title>Coffee as a Treatment Â· Darren Cohen</title>

    <link rel="stylesheet" href="/css/site.css">
    <link rel="alternate" type="application/rss+xml" title="Darren Cohen RSS" href="/index.xml">
  <link rel="icon" type="image/png" sizes="32x32" href="/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png">
<link rel="apple-touch-icon" href="/apple-touch-icon.png">

<meta name="title" content="Coffee as a Treatment | Darren Cohen">
<meta name="description" content="Darren Cohen">

<meta property="og:type" content="website">
<meta property="og:title" content="Coffee as a Treatment | Darren Cohen">
<meta property="og:description" content="Darren Cohen">
<meta property="og:image" content="http://localhost:1313/og.jpg">
<meta property="og:url" content="http://localhost:1313/blog/coffee-as-a-treatment/">

<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:title" content="Coffee as a Treatment | Darren Cohen">
<meta name="twitter:description" content="Darren Cohen">
<meta name="twitter:image" content="http://localhost:1313/og.jpg">

  </head>
  <body>
    <main class="wrap">
      <header class="site-header">
  <a class="brand" href="/">Darren Cohen</a>
  <nav class="nav">
    <a href="/blog/">Blog</a>
    <a href="/things-i-use/">Apps/Services</a>
    <a href="/recommended/">Recommended</a>
  </nav>
</header>

      <article class="content">
        
  <h1>
    
      <a href="https://arstechnica.com/health/2026/01/placebo-outperforms-lsd-microdosing-for-depression/" target="_blank" rel="noopener">ğŸ”— Coffee as a Treatment</a>
    
  </h1>
  <p class="meta">
    Feb 1, 2026 Â· 7:45am
     Â· Ars Tehnica
    Â· <a href="/blog/coffee-as-a-treatment/">Permalink</a>
  </p>

  <blockquote>
<p>The study has not yet been published. But MindBioâ€™s CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was â€œin front of the curve in microdosing research.â€ He called it â€œthe most vigorous placebo controlled trial ever performed in microdosing.â€ It found that patients dosed with a small amount of LSD (ranging from 4 to 20Î¼g, or micrograms, well below the threshold of a mind-blowing hallucinogenic dose) showed observable upticks in feelings of well-being, but worse MADRS scores, compared to patients given a placebo in the form of a caffeine pill. (Because patients in psychedelic trials typically expect some kind of mind-altering effect, studies are often blinded using so-called â€œactive placebos,â€ like caffeine or methylphenidate, which have their own observable psychoactive properties.)</p>
</blockquote>
<blockquote>
<p>This means, essentially, that a medium-strength cup of coffee may prove more beneficial in treating major depressive disorder than a tiny dose of acid. Good news for habitual caffeine users, perhaps, but less so for researchers (and biopharma startups) counting on the efficacy of psychedelic microdosing.</p>
</blockquote>
<p>â€”</p>
<p>Well given the amount of coffee I drink, I will approve of this study. Will take any help I can get. Also, someone tell Elon!</p>


  
    <p><a href="https://arstechnica.com/health/2026/01/placebo-outperforms-lsd-microdosing-for-depression/" target="_blank" rel="noopener">Read the original â†’</a></p>
  

      </article>
      <footer class="footer">
  <p>
    <small>
      Â© 2026 Darren Cohen Â· Built with
      <a href="https://gohugo.io/" target="_blank" rel="noopener">Hugo</a>, hosted on
      <a href="https://github.com/" target="_blank" rel="noopener">GitHub</a>
    </small>
  </p>
</footer>

    </main>
  </body>
</html>
